Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Crinetics has achieved significant milestones in 2025, marking it as a breakthrough year for the company [3] - The company successfully obtained approval for a broad label for Palsonify, aimed at treating acromegaly, coinciding with its PDUFA date [3] Company Development - Crinetics has evolved from discussing its first molecule, CRN808, to focusing on Palsonify and building a comprehensive pipeline and business [2] - The management emphasizes the transition from merely developing drugs to establishing a sustainable business model [2]